Payment overview · 2025
General Payments
$3,222.69
136 reported records · 18 companies
Healthcare provider profile · identity verified
Ko Kim, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · GREENSBORO, NC · NPI 1811668841
Verified facts
What the public records show
CMS Open Payments records show Ko Kim, NP received $3,222.69 in general payments during 2025 across 136 reported records.
SI-BONE, INC. accounted for 16.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Movantik, Nurtec Odt, Qulipta, Relistor, Ubrelvy, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nurtec Odt by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Relistor by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $537.24 | 16.7% | 2 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $393.81 | 12.2% | 29 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $367.99 | 11.4% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $257.57 | 8.0% | 12 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $225.18 | 7.0% | 14 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$216.99 | 6.7% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $193.11 | 6.0% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $192.69 | 6.0% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $181.35 | 5.6% | 4 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $163.22 | 5.1% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $148.26 | 4.6% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $138.68 | 4.3% | 11 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $48.59 | 1.5% | 2 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $44.69 | 1.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $44.30 | 1.4% | 2 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.85 | 1.1% | 1 | 2025 |
| Virtus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.38 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.79 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,657.77 | 134 |
| Travel and Lodging | $521.97 | 1 |
| Education | $42.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IFUSE IMPLANT SYSTEM Normalized: ifuse implant system |
Device | SI-BONE, INC. | $521.97 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $393.81 | 29 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $257.57 | 12 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $216.99 | 6 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $212.37 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $193.11 | 15 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $192.93 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $192.69 | 12 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $181.35 | 4 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $163.22 | 8 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $163.22 | 8 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $163.22 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $150.65 | 10 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $148.26 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $138.68 | 11 | 2025 |
Source payment records
|
|||||
| Vyrsa V1 Normalized: vyrsa v1 |
Device | Globus Medical, Inc. | $92.79 | 3 | 2025 |
Source payment records
|
|||||
| OMNIA Normalized: omnia |
Device | Globus Medical, Inc. | $62.83 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $48.59 | 2 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $42.04 | 2 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $33.85 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $32.25 | 2 | 2025 |
Source payment records
|
|||||
| LEVORPHANOL TARTRATE Normalized: levorphanol tartrate |
Drug | Virtus Pharmaceuticals LLC | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOVANTIK movantik |
2025 | Movantik | 2024 | 34 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
85 | 29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1033 | 158 |
| Oxycodone Hcl | Oxycodone Hcl | 646 | 82 |
| Xtampza Er | Oxycodone Myristate | 387 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 66 |
| Gabapentin | Gabapentin | 293 | 67 |
| Pregabalin | Pregabalin | 180 | 42 |
| Buprenorphine | Buprenorphine | 158 | 39 |
| Morphine Sulfate Er | Morphine Sulfate | 147 | 25 |
| Meloxicam | Meloxicam | 138 | 22 |
| Naloxone Hcl | Naloxone Hcl | 96 | 88 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 20 |
| Ztlido | Lidocaine | 85 | 29 |
| Baclofen | Baclofen | 79 | 27 |
| Tramadol Hcl | Tramadol Hcl | 77 | 17 |
| Oxycontin | Oxycodone Hcl | 75 | 11 |
| Belbuca | Buprenorphine Hcl | 60 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 14 |
| Topiramate | Topiramate | 57 | 11 |
| Linzess | Linaclotide | 56 | 13 |
| Lidocaine | Lidocaine | 55 | 18 |
| Nucynta Er | Tapentadol Hcl | 50 | suppressed |
| Levetiracetam | Levetiracetam | 45 | suppressed |
| Relistor | Methylnaltrexone Bromide | 39 | suppressed |
| Methadone Hcl | Methadone Hcl | 38 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 35 | suppressed |
| Movantik | Naloxegol Oxalate | 34 | 13 |
| Horizant | Gabapentin Enacarbil | 32 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 32 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 30 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 25 | suppressed |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 23 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 22 | suppressed |
| Qulipta | Atogepant | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Gralise | Gabapentin | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Topiramate Er | Topiramate | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Nucynta | Tapentadol Hcl | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,222.69 · 136 records | SI-BONE, INC. | BOTOX, BRIUMVI, Briviact, EPIDIOLEX, IFUSE IMPLANT SYSTEM, INGREZZA, INSPIRE, JOURNAVX, KESIMPTA, LEVORPHANOL TARTRATE, MOVANTIK, NALOCET, NURTEC ODT, OMNIA, PROLATE, QULIPTA, RELISTOR, Senza, Sunosi, TANLOR, UBRELVY, VALTOCO, Vyrsa V1, XYWAV, ZAVZPRET, ZTLido | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Movantik play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error